Nyxoah reports Q2 EPS (EUR 0.55) vs. (EUR 0.43) last year

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for Nyxoah (NYXH) and marks the beginning of what we expect to be a transformational period for our company,” commented Olivier Taelman, Nyxoah’s CEO. “Genio is now the first and only bilateral hypoglossal neurostimulation therapy approved in the United States, offering a truly differentiated solution for OSA patients who have been underserved by existing therapies. Our world-class commercial team is in place, and we have begun to execute on our commercial strategy.”